<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01837433</url>
  </required_header>
  <id_info>
    <org_study_id>XinqiaoH-001</org_study_id>
    <nct_id>NCT01837433</nct_id>
  </id_info>
  <brief_title>Short-term Prednisone to Treat STA Study(SPTSS)</brief_title>
  <acronym>STA</acronym>
  <official_title>Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute
      Thyroiditis

      The investigators hypothesize that less adverse reactions will be observed, comparing with
      the guidelines recommend. The recurrence rate, adrenal insufficiency, temporary and permanent
      hypothyroidism aren't significant difference.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparing with the guidelines recommend, short-term (one week)prednisone and nsaids following
      up next week to treat moderate and severe subacute thyroiditis will be assessed.

      The patients in wards will be assessed from temperature,erythrocyte sedimentation
      rate,C-reactive protein,local pain and goiter.The random treatment will be executed in
      moderate and severe SAT after informed consent be signed.

      Subjects will be monitored once every 2 weeks.If patients complained of pain in their neck or
      if the erythrocyte sedimentation rate is still high,after discontinuation of prednisone,
      prednisone treatment will be resumed in moderate and severe subject and non-steroidal
      anti-inflammatory drugs will be used in mild subject.Anti-ulcer drugs will be administered to
      all patients.

      The endpoint of the study are efficiency and safety of short-term prednisone treating. The
      investigators will assess adrenal insufficiency (such as anorexia, nausea, vomiting,
      abdominal pain),steroid withdrawal syndrome, recurrence rate and hypothyroidism. The
      investigators will observe erythrocyte sedimentation rate,pain,steroid level and thyroid
      function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Efficiency of experimental group comparing with control group during 14 days</measure>
    <time_frame>14 days</time_frame>
    <description>We will observe change of erythrocyte sedimentation rate from &gt;20mm/h to normal,C-reactive protein,pain and goiter disappear after 14 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrence rate</measure>
    <time_frame>180 days</time_frame>
    <description>The recurrence will be defined:local tenderness, goiter, inflammatory factors such as erythrocyte sedimentation rate, C-reactive protein increased during 180 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypothyroidism</measure>
    <time_frame>180 days</time_frame>
    <description>change in thyroid function:from hyperthyroidism on baseline to hypothyroidism after 180 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adrenal insufficiency after withdraw in experimental group and control group.</measure>
    <time_frame>42 days</time_frame>
    <description>The Symptom such as anorexia, nausea, vomiting, abdominal pain, fatigue, weakness, collapse, muscle pain, joint pain, weight loss, orthostatic hypotension, lethargy and depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of blood glucose in experimental group and control group.</measure>
    <time_frame>42 days</time_frame>
    <description>Glucose change when taking medicine:from normal blood glucose on baseline to hyperglycemia at the special time during medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of blood pressure in experimental and control group during medication.</measure>
    <time_frame>42 days</time_frame>
    <description>We will measure blood pressure before and after withdraw prednisone in experimental and control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone metabolism after withdraw in experimental group and control group.</measure>
    <time_frame>42 days</time_frame>
    <description>We will measure Bone metabolism markers before and after withdraw prednisone in experimental and control group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Lipids in experimental and control group during medication.</measure>
    <time_frame>42 days</time_frame>
    <description>We will measure Lipids before and after withdraw prednisone in experimental and control group.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Other side effects of prednisone</measure>
    <time_frame>42 days</time_frame>
    <description>Such as,cushing appearance; female hirsutism, menstrual disorders, impotence in men; gastrointestinal ulcers; psychiatric symptoms: anxiety, agitation, fatigue</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Subacute Thyroiditis</condition>
  <arm_group>
    <arm_group_label>Prednisone 1 week</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisone 6 weeks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral 30 mg/day of prednisone will be administered as the initial dose for the treatment of SAT in first week,then tapered by 5mg every 1 week,the duration of prednisone will be 6 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone 1 week</intervention_name>
    <description>Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.</description>
    <arm_group_label>Prednisone 1 week</arm_group_label>
    <other_name>Glucocorticoid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone 6 weeks</intervention_name>
    <description>Guidelines recommend</description>
    <arm_group_label>Prednisone 6 weeks</arm_group_label>
    <other_name>Glucocorticoid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-70 years patients with Moderate and severe subacute thyroiditis

        Exclusion Criteria:

          -  adrenal cortical dysfunction,

          -  use of corticosteroids in nearly three months,

          -  mild subacute thyroiditis,

          -  non-onset STA,

          -  family history of diabetes,

          -  gastric ulcer,

          -  the special medication history,

          -  heartï¼Œliver and renal insufficiency,

          -  tumors,

          -  tuberculosis and

          -  poor compliance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongting Zheng, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology, The Second Affiliated Hospital, Third Military Medical University, Chongqing, People's Republic of China.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Second Affiliated Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Kubota S, Nishihara E, Kudo T, Ito M, Amino N, Miyauchi A. Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan. Thyroid. 2013 Mar;23(3):269-72. doi: 10.1089/thy.2012.0459.</citation>
    <PMID>23227861</PMID>
  </results_reference>
  <results_reference>
    <citation>Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003 May;88(5):2100-5.</citation>
    <PMID>12727961</PMID>
  </results_reference>
  <results_reference>
    <citation>Nishihara E, Ohye H, Amino N, Takata K, Arishima T, Kudo T, Ito M, Kubota S, Fukata S, Miyauchi A. Clinical characteristics of 852 patients with subacute thyroiditis before treatment. Intern Med. 2008;47(8):725-9. Epub 2008 Apr 16.</citation>
    <PMID>18421188</PMID>
  </results_reference>
  <results_reference>
    <citation>Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN; American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011 Jun;21(6):593-646. doi: 10.1089/thy.2010.0417. Epub 2011 Apr 21. Erratum in: Thyroid. 2011 Oct;21(10):1169. Thyroid. 2012 Nov;22(11):1195.</citation>
    <PMID>21510801</PMID>
  </results_reference>
  <results_reference>
    <citation>Nishihara E, Amino N, Ohye H, Ota H, Ito M, Kubota S, Fukata S, Miyauchi A. Extent of hypoechogenic area in the thyroid is related with thyroid dysfunction after subacute thyroiditis. J Endocrinol Invest. 2009 Jan;32(1):33-6.</citation>
    <PMID>19337012</PMID>
  </results_reference>
  <results_reference>
    <citation>Iitaka M, Momotani N, Ishii J, Ito K. Incidence of subacute thyroiditis recurrences after a prolonged latency: 24-year survey. J Clin Endocrinol Metab. 1996 Feb;81(2):466-9.</citation>
    <PMID>8636251</PMID>
  </results_reference>
  <results_reference>
    <citation>Vagenakis AG, Abreau CM, Braverman LE. Prevention of recurrence in acute thyoiditis following corticosteroid withdrawal. J Clin Endocrinol Metab. 1970 Dec;31(6):705-8.</citation>
    <PMID>4098399</PMID>
  </results_reference>
  <results_reference>
    <citation>VolpÃ© R. The management of subacute (DeQuervain's) thyroiditis. Thyroid. 1993 Fall;3(3):253-5. Review.</citation>
    <PMID>8257868</PMID>
  </results_reference>
  <results_reference>
    <citation>Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003 Jun 26;348(26):2646-55. Review. Erratum in: N Engl J Med. 2003 Aug 7;349(6):620.</citation>
    <PMID>12826640</PMID>
  </results_reference>
  <results_reference>
    <citation>Desailloud R, Hober D. Viruses and thyroiditis: an update. Virol J. 2009 Jan 12;6:5. doi: 10.1186/1743-422X-6-5. Review.</citation>
    <PMID>19138419</PMID>
  </results_reference>
  <results_reference>
    <citation>Mizukoshi T, Noguchi S, Murakami T, Futata T, Yamashita H. Evaluation of recurrence in 36 subacute thyroiditis patients managed with prednisolone. Intern Med. 2001 Apr;40(4):292-5.</citation>
    <PMID>11334386</PMID>
  </results_reference>
  <results_reference>
    <citation>Benbassat CA, Olchovsky D, Tsvetov G, Shimon I. Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005. J Endocrinol Invest. 2007 Sep;30(8):631-5.</citation>
    <PMID>17923793</PMID>
  </results_reference>
  <results_reference>
    <citation>Carella MJ, Srivastava LS, Gossain VV, Rovner DR. Hypothalamic-pituitary-adrenal function one week after a short burst of steroid therapy. J Clin Endocrinol Metab. 1993 May;76(5):1188-91.</citation>
    <PMID>8388401</PMID>
  </results_reference>
  <results_reference>
    <citation>Alves C, Robazzi TC, MendonÃ§a M. Withdrawal from glucocorticosteroid therapy: clinical practice recommendations. J Pediatr (Rio J). 2008 May-Jun;84(3):192-202. doi: doi:10.2223/JPED.1773. Review.</citation>
    <PMID>18535733</PMID>
  </results_reference>
  <results_reference>
    <citation>Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA. 1999 Aug 18;282(7):671-6.</citation>
    <PMID>10517721</PMID>
  </results_reference>
  <results_reference>
    <citation>Henzen C, Suter A, Lerch E, Urbinelli R, Schorno XH, Briner VA. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet. 2000 Feb 12;355(9203):542-5.</citation>
    <PMID>10683005</PMID>
  </results_reference>
  <results_reference>
    <citation>Longui CA. Glucocorticoid therapy: minimizing side effects. J Pediatr (Rio J). 2007 Nov;83(5 Suppl):S163-77. Epub 2007 Nov 14. Review.</citation>
    <PMID>18000630</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2013</study_first_submitted>
  <study_first_submitted_qc>April 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2013</study_first_posted>
  <last_update_submitted>May 18, 2015</last_update_submitted>
  <last_update_submitted_qc>May 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Lian Duan</investigator_full_name>
    <investigator_title>Clinical Doctor</investigator_title>
  </responsible_party>
  <keyword>Efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>short</keyword>
  <keyword>term</keyword>
  <keyword>subacute thyroiditis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroiditis</mesh_term>
    <mesh_term>Thyroiditis, Subacute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

